{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Tsang RS"],"funding":["Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation","Medical Research Council"],"pagination":["134-148"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11100448"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["117(4)"],"pubmed_abstract":["<h4>Objectives</h4>To estimate the incidence of adverse events of interest (AEIs) after receiving their first and second doses of coronavirus disease 2019 (COVID-19) vaccinations, and to report the safety profile differences between the different COVID-19 vaccines.<h4>Design</h4>We used a self-controlled case series design to estimate the relative incidence (RI) of AEIs reported to the Oxford-Royal College of General Practitioners national sentinel network. We compared the AEIs that occurred seven days before and after receiving the COVID-19 vaccinations to background levels between 1 October 2020 and 12 September 2021.<h4>Setting</h4>England, UK.<h4>Participants</h4>Individuals experiencing AEIs after receiving first and second doses of COVID-19 vaccines.<h4>Main outcome measures</h4>AEIs"],"journal":["Journal of the Royal Society of Medicine"],"pubmed_title":["Adverse events after first and second doses of COVID-19 vaccination in England: a national vaccine surveillance platform self-controlled case series study."],"pmcid":["PMC11100448"],"funding_grant_id":["HDRUK2021.0056","MC_PC_20058","MC_PC_20029"],"pubmed_authors":["O'Reilly D","Agrawal U","Chuter A","Richard Hobbs FD","Joy M","Williams J","Victor W","Anand SN","Beggs J","Sheikh A","Howsam G","Kar D","Lusignan S","Akbari A","Robertson C","Hinton W","Tsang RS","Mayor N","Owen RK","Bradley DT","Byford R","Murphy S"],"additional_accession":[]},"is_claimable":false,"name":"Adverse events after first and second doses of COVID-19 vaccination in England: a national vaccine surveillance platform self-controlled case series study.","description":"<h4>Objectives</h4>To estimate the incidence of adverse events of interest (AEIs) after receiving their first and second doses of coronavirus disease 2019 (COVID-19) vaccinations, and to report the safety profile differences between the different COVID-19 vaccines.<h4>Design</h4>We used a self-controlled case series design to estimate the relative incidence (RI) of AEIs reported to the Oxford-Royal College of General Practitioners national sentinel network. We compared the AEIs that occurred seven days before and after receiving the COVID-19 vaccinations to background levels between 1 October 2020 and 12 September 2021.<h4>Setting</h4>England, UK.<h4>Participants</h4>Individuals experiencing AEIs after receiving first and second doses of COVID-19 vaccines.<h4>Main outcome measures</h4>AEIs","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2026-04-12T15:30:34.516Z","creation":"2026-04-07T13:18:01.449Z"},"accession":"S-EPMC11100448","cross_references":{"pubmed":["37921538"],"doi":["10.1177/01410768231205430"]}}